SAT1 and glioblastoma multiforme: Disarming the resistance

Glioblastoma multiforme is the most common and most detrimental form of brain tumor, with a current survival time of as little as 14 months. We have recently identified a novel mechanism of therapeutic resistance based on overexpression of the polyamine catabolic enzyme spermidine/spermine N1-acetyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Brett-Morris, Adina, Mislmani, Mazen, Welford, Scott M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905296/
https://www.ncbi.nlm.nih.gov/pubmed/27308461
http://dx.doi.org/10.4161/23723556.2014.983393
_version_ 1782437242148487168
author Brett-Morris, Adina
Mislmani, Mazen
Welford, Scott M
author_facet Brett-Morris, Adina
Mislmani, Mazen
Welford, Scott M
author_sort Brett-Morris, Adina
collection PubMed
description Glioblastoma multiforme is the most common and most detrimental form of brain tumor, with a current survival time of as little as 14 months. We have recently identified a novel mechanism of therapeutic resistance based on overexpression of the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase, which promotes DNA repair via chromatin modification.
format Online
Article
Text
id pubmed-4905296
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052962016-06-15 SAT1 and glioblastoma multiforme: Disarming the resistance Brett-Morris, Adina Mislmani, Mazen Welford, Scott M Mol Cell Oncol Author's Views Glioblastoma multiforme is the most common and most detrimental form of brain tumor, with a current survival time of as little as 14 months. We have recently identified a novel mechanism of therapeutic resistance based on overexpression of the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase, which promotes DNA repair via chromatin modification. Taylor & Francis 2015-01-23 /pmc/articles/PMC4905296/ /pubmed/27308461 http://dx.doi.org/10.4161/23723556.2014.983393 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's Views
Brett-Morris, Adina
Mislmani, Mazen
Welford, Scott M
SAT1 and glioblastoma multiforme: Disarming the resistance
title SAT1 and glioblastoma multiforme: Disarming the resistance
title_full SAT1 and glioblastoma multiforme: Disarming the resistance
title_fullStr SAT1 and glioblastoma multiforme: Disarming the resistance
title_full_unstemmed SAT1 and glioblastoma multiforme: Disarming the resistance
title_short SAT1 and glioblastoma multiforme: Disarming the resistance
title_sort sat1 and glioblastoma multiforme: disarming the resistance
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905296/
https://www.ncbi.nlm.nih.gov/pubmed/27308461
http://dx.doi.org/10.4161/23723556.2014.983393
work_keys_str_mv AT brettmorrisadina sat1andglioblastomamultiformedisarmingtheresistance
AT mislmanimazen sat1andglioblastomamultiformedisarmingtheresistance
AT welfordscottm sat1andglioblastomamultiformedisarmingtheresistance

Ejemplares similares